Factor V Leiden and myocardial infarction: A case, review of the litterature with a meta-analysis;Facteur V Leiden et infarctus du myocarde: À propos d'un cas, revue systématique de la littérature et méta-analyse

Annales de Cardiologie et d'Angeiologie

Volumn 52, Issue 3, 2003, Pages 143-149

  Doix, S ^a   Mahrousseh, M ^b   Jolak, M ^a   Laurent, Y ^a   Lorenzini, J L ^c   Binquet, C ^c   Zeller, M ^d   Cottin, Y ^d   Wolf, J E ^d  

^a Hôpital R Morlevat   (France)

^b CENTRE HOSPITALIER   (France)

^c HÔPITAL DU BOCAGE   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Factor V Leiden; Meta analysis; Myocardial infarction

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CASE REPORT; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; MALE; META ANALYSIS; PATHOGENESIS; PREVALENCE; VEIN THROMBOSIS;

EID: 0038727927     PISSN: 00033928     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-3928(02)00192-0     Document Type: Short Survey

References (31)

1. Bertina RM, Koelman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
2. Griffin JH, Evatt B, Widemann C, Fernandes JA. Anticoagulant Potein C pathway defective in the majority of thrombophilie patients. Blood 1993;82:1989-93.
3. Koster T, Rosendaal FR, De Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden Thrombophilia study. Lancet 1993;342:1503-6.
4. Doggen CJM, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors. Increased risk of myocardial infraction associated with factor V Leiden or prothrombin 20210A. Circulation 1998;97:1037-41.
5. Prohaska W, Mannebach H, Schmidt M, Gleichman U, Kleesiek K. Evidence against heterozygous coagulation factor V 169 G→A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. J Mol Med 1995; 73:512-4.
6. Redondo M, Watzke HH, Stucki B, Sultzer I, et al. Coagulation factor II., V., VII and X., prothrombin gene 20210 G→A transition, and factor V Leiden in coronary artery disease: High factor V clotting activity is an independant risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:1020-5.
7. Feng YJ, Draghi A, Linfert DR, Wu AHB, Tsongalis GJ. Polymorphisms in the genes for coagulation factors II, V and VII in patients with ischemique heart disease. Arch pathol Lab Med 1999;123: 1230-5.
8. Gowda MS, Zucker ML, et al. Incidence of factor V Leiden in patients with acute myocardial infraction. J Thrombosis Thrombolysis 2000; 9:43-5.
9. Makris TK, Krespi PG, Hatzizacharias AN, et al. Resistance to activated protein C and factor V Leiden mutation in patients with a history of acute myocardial infarction or primary hypertension. Am J Hypertens 2000;13:61-5.
10. Emmerich J, Poirier O, Evan, et al. Myocardial infarction, Arg 506 to Gln factor V mutation and activated protein C resistance. Lancet 1995;345:321.
11. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and veinous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
12. Heijmann BT, Westendorp RG, Knook DL, Kluft G, Slagboom PE. The risk of mortality and the factor V Leiden mutation in a population based cohort. Thromb Haemost 1998;80:607-9.
13. Hansson PO, Eriksson E, Welin L, Eriksson H. Prevalence of APC resistance and its relationship to arterial and venous thromboembolism in a general population sample of elderly switchen men: the study of men born in 1913. J Inter Med 1999;245:593-600.
14. Roest M, Banga JD, Tempelman MJ, et al. Factor V Arg 506 Gln mutation is not associated with cardiovascular mortality in older women. Americain Jourmal of Epidemiology 1999;149:665-6701.
15. Baranovskaya S, Kudinov S, Formicheva E, et al. Age as a risk factor for myocardial infarction in Leiden mutation carriers. Molecular genetics and metabolism 1998;63:155-7.
16. Marz W, Seydewitz H, Winkekmann B, et al. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995;345:526-7.
17. Van Bockxmeer FM, Baker RI, Taylor RR. Is factor V Leiden a role factor for premature ischemic heart disease?. Thromb Haemost 1995; 73:1373.
18. Holm J, Zoller B, Berntorp, Erhardt L, Dahlback B. Prevalence of factor V gene mutation amongst myocardial infarction in patients and healthy controls is higher in Sweden than in other countries. J Intern Med 1996;239:221-6.
19. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;86:2817-21.
20. Junker R, Heinrich J, Schulte H, et al. Plasminogen activator-inhibitor-1 4G/5G-polymorphism and factor V Q 506 mutation are not associated with myocardial infarction in young men. Blood Coag Fibrinolysis 1998;9:597-602.
21. Amowitz LL, Komaroff AL, Miletich JP, Ridker PM, Factor V. Leiden is not a risk factor among young women (letter). Blood 1999;93:1432-3.
22. Ardissino D, Mannucci PM, Merlini PA, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999;94:46-51.
23. Inbal A, Freimark D, Modan B, et al. Synergistic effect of prothrombotic polymorphisms and atherogenic factor on the risk of myocardial infarction in young males. Blood 1999;93:2186-90.
24. Lande G, Dantec V, Trossaert M, Godin JF, Le Marec H. Do inherited prothrombotic factors have a role in myocardial infarction with normal coronary arteriogram?. J Intern Med 1998;244:543-5.
25. Da Costa A, Tardy-Poncet B, Izaak K, et al. Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries. Heart 1998;80:338-40.
26. Mansourati J, Da Costa A, Munier S, et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000;83:822-5.
27. Van De Waters NS, French JK, Lund M, et al. Prevalence of factor V Leiden and prothrombin variant G20210A in patient age < 50 years with no significant stenosis at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol 2000;36:717-22.
28. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997;126:638-44.
29. Alpert JS. Myocardial infarction with angiographically normal coronary arteries. Arch Intern Med 1994;154:265-9.
30. Bayes-Genis A, et al. Pregnancy-Associated Plasma Protein A as a marker of Acute Coronary Syndromes. NEJM 2001;345:14.
31. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) research group, Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.